Cargando…
Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats
BACKGROUND/AIM: The aim of this study is to determine the effects of different concentrations of albendazole and lansoprazole, which were benzimidazole derivatives, on endocrinologic and biochemical parameters in experimental type 2 diabetic (T2D) rats. MATERIALS AND METHODS: In this study, 46 male...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific and Technological Research Council of Turkey
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283501/ https://www.ncbi.nlm.nih.gov/pubmed/33641315 http://dx.doi.org/10.3906/sag-2004-38 |
_version_ | 1783723217369694208 |
---|---|
author | DİK, Burak COŞKUN, Devran BAHÇİVAN, Emre ÜNEY, Kamil |
author_facet | DİK, Burak COŞKUN, Devran BAHÇİVAN, Emre ÜNEY, Kamil |
author_sort | DİK, Burak |
collection | PubMed |
description | BACKGROUND/AIM: The aim of this study is to determine the effects of different concentrations of albendazole and lansoprazole, which were benzimidazole derivatives, on endocrinologic and biochemical parameters in experimental type 2 diabetic (T2D) rats. MATERIALS AND METHODS: In this study, 46 male Wistar Albino rats were used. Animals were divided as healthy control (0.1 mL/rat/day saline, s.c, n = 6), diabetes control (0.1 mL/rat/day saline, s.c, n = 8), diabetes+low-dose albendazole (5 mg/kg, oral, n = 8), diabetes+high-dose albendazole (10 mg/kg, oral n = 8), diabetes+low-dose lansoprazole (15 mg/kg, subcutaneous, n = 8), and diabetes+high-dose lansoprazole (30 mg/kg, subcutaneous, n = 8). All groups were treated for 8 weeks. The blood samples were analyzed by autoanalyzer and ELISA kits for biochemical and endocrinological parameters, respectively. RESULTS: Glucose, HbA1c, triglyceride, low density cholesterol (LDL), leptin, and Homeostatic Model Assessment for insulin resistance (HOMA-IR) levels increased and insulin and HOMA-β levels decreased in the diabetic rats compared to the healthy control group. The glucose, HbA1c, and triglyceride levels were partially decreased; however, insulin and HOMA-β levels were increased by low-dose albendazole therapy. The high dose of lansoprazole treatment increased insulin level. CONCLUSION: The lansoprazole and albendazole treatments can be a potential drug or combined with antidiabetic drugs in T2D treatment by Adenosine 5 ′ -monophosphate activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), incretin-like effect and other antidiabetic mechanisms. It may be beneficial to create an effective treatment strategy by developing more specific substances with benzimidazole scaffold. |
format | Online Article Text |
id | pubmed-8283501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Scientific and Technological Research Council of Turkey |
record_format | MEDLINE/PubMed |
spelling | pubmed-82835012021-08-02 Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats DİK, Burak COŞKUN, Devran BAHÇİVAN, Emre ÜNEY, Kamil Turk J Med Sci Article BACKGROUND/AIM: The aim of this study is to determine the effects of different concentrations of albendazole and lansoprazole, which were benzimidazole derivatives, on endocrinologic and biochemical parameters in experimental type 2 diabetic (T2D) rats. MATERIALS AND METHODS: In this study, 46 male Wistar Albino rats were used. Animals were divided as healthy control (0.1 mL/rat/day saline, s.c, n = 6), diabetes control (0.1 mL/rat/day saline, s.c, n = 8), diabetes+low-dose albendazole (5 mg/kg, oral, n = 8), diabetes+high-dose albendazole (10 mg/kg, oral n = 8), diabetes+low-dose lansoprazole (15 mg/kg, subcutaneous, n = 8), and diabetes+high-dose lansoprazole (30 mg/kg, subcutaneous, n = 8). All groups were treated for 8 weeks. The blood samples were analyzed by autoanalyzer and ELISA kits for biochemical and endocrinological parameters, respectively. RESULTS: Glucose, HbA1c, triglyceride, low density cholesterol (LDL), leptin, and Homeostatic Model Assessment for insulin resistance (HOMA-IR) levels increased and insulin and HOMA-β levels decreased in the diabetic rats compared to the healthy control group. The glucose, HbA1c, and triglyceride levels were partially decreased; however, insulin and HOMA-β levels were increased by low-dose albendazole therapy. The high dose of lansoprazole treatment increased insulin level. CONCLUSION: The lansoprazole and albendazole treatments can be a potential drug or combined with antidiabetic drugs in T2D treatment by Adenosine 5 ′ -monophosphate activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), incretin-like effect and other antidiabetic mechanisms. It may be beneficial to create an effective treatment strategy by developing more specific substances with benzimidazole scaffold. The Scientific and Technological Research Council of Turkey 2021-06-28 /pmc/articles/PMC8283501/ /pubmed/33641315 http://dx.doi.org/10.3906/sag-2004-38 Text en Copyright © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Article DİK, Burak COŞKUN, Devran BAHÇİVAN, Emre ÜNEY, Kamil Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats |
title | Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats |
title_full | Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats |
title_fullStr | Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats |
title_full_unstemmed | Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats |
title_short | Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats |
title_sort | potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283501/ https://www.ncbi.nlm.nih.gov/pubmed/33641315 http://dx.doi.org/10.3906/sag-2004-38 |
work_keys_str_mv | AT dikburak potentialantidiabeticactivityofbenzimidazolederivativealbendazoleandlansoprazoledrugsindifferentdosesinexperimentaltype2diabeticrats AT coskundevran potentialantidiabeticactivityofbenzimidazolederivativealbendazoleandlansoprazoledrugsindifferentdosesinexperimentaltype2diabeticrats AT bahcivanemre potentialantidiabeticactivityofbenzimidazolederivativealbendazoleandlansoprazoledrugsindifferentdosesinexperimentaltype2diabeticrats AT uneykamil potentialantidiabeticactivityofbenzimidazolederivativealbendazoleandlansoprazoledrugsindifferentdosesinexperimentaltype2diabeticrats |